Goldman Sachs’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Goldman Sachs’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-45,700	Closed	-$775K	–	7582
2014 Q4	$775K	Sell	45,700 -268,100	-85%	-$3.77M	﹤0.01%	4852
2014 Q3	$3.74M	Buy	313,800 +270,500	+625%	+$1.85M	﹤0.01%	3314
2014 Q2	$244K	Sell	43,300 -585,200	-93%	-$2.7M	﹤0.01%	6041
2014 Q1	$2.31M	Buy	628,500 +461,400	+276%	+$1.76M	﹤0.01%	3836
2013 Q4	$561K	Buy	167,100 +158,400	+1,821%	+$654K	﹤0.01%	5218
2013 Q3	$37K	Sell	8,700 -79,800	-90%	-$378K	﹤0.01%	6361
2013 Q2	$407K	Buy	+88,500	New	+$304K	﹤0.01%	5113

Goldman Sachs's AVNR Position: Q1 2015 in Review

Goldman Sachs sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 337,576 shares — an estimated $5.72M sold.

Goldman Sachs first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $10.5M in Q3 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

Goldman Sachs reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
Goldman Sachs sold 337,576 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $5.72M.
Goldman Sachs first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
Goldman Sachs's AVANIR PHARMACEUTICALS, INC CL A position peaked at $10.5M in Q3 2014.
0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Goldman Sachs's 13F filing for Q1 2015, filed 15 May 2015.